

Gut Dysbiosis and Hemodynamic Changes as Links of the Pathogenesis of Complications of Cirrhosis

Roman Maslennikov (✉ mmmm00@yandex.ru)

Sechenov University <https://orcid.org/0000-0001-7513-1636>

Vladimir Ivashkin

Sechenov University

Irina Efremova

Sechenov University

Elena Poluektova

Sechenov University

Elena Shirokova

Sechenov University

Konstantin Ivashkin

Sechenov University: Pervyj Moskovskij gosudarstvennyj medicinskij universitet imeni I M Sechenova

Anna Kudryavtseva

Institute of Molecular Biology V.A.Engelhardt

George Biology V.A.Engelhardt Krasnov

Inscitutr of Molecular Biology V.A.Engelhardt

Research Article

Keywords: Gut-liver axis, Microbiome, Microbiota, Bacteria, Hemodynamics, Gut-heart axis, Heart, Gut, Circulation, Translocation.

Posted Date: July 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-713570/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background. Hemodynamic changes (hyperdynamic circulation) and gut dysbiosis are observed in cirrhosis. It was suggested that gut dysbiosis contributes to the development of hyperdynamic circulation, which aggravates the course of cirrhosis. The aim is to test this hypothesis.

Methods. The cross-sectional observational study included 47 patients with cirrhosis. Stool microbiome was assessed using 16S rRNA gene sequencing. Echocardiography with a simultaneous assessment of blood pressure and heart rate was performed. Hemodynamic parameters were calculated.

Results. Hyperdynamic circulation was found in 34% of patients. Patients with hyperdynamic circulation had higher incidences of clinically significant ascites ($p=0.018$), overt hepatic encephalopathy ($p=0.042$), hypoalbuminemia ($p=0.011$), hypoprothrombinemia ($p=0.019$), systemic inflammation ($p=0.002$), and severe hyperbilirubinemia ($p=0.042$) than patients without hyperdynamic circulation. The abundance of Proteobacteria ($p=0.012$), *Enterobacteriaceae* ($p=0.008$), Bacilli ($p=0.027$), *Streptococcaceae* ($p=0.044$), *Lactobacillaceae* ($p=0.034$), *Enterococcaceae* ($p=0.046$), and Fusobacteria ($p=0.026$) increased and the abundance of Bacteroidetes ($p=0.049$) and Erysipelotrichia ($p=0.029$) decreased in the gut microbiome of patients with hyperdynamic circulation compared to patients without hyperdynamic circulation. The systemic vascular resistance value negatively correlated with the abundance of Proteobacteria ($r=-0.423$; $p=0.003$), *Enterobacteriaceae* ($r=-0.417$; $p=0.004$), and Fusobacteria ($r=-0.401$; $p=0.005$). Heart rate was negatively correlated with the abundance of Bacteroidetes ($r=-0.453$; $p=0.001$). The cardiac output value was positively correlated with the abundance of Proteobacteria ($r=0.402$; $p=0.003$), *Enterobacteriaceae* ($r=0.424$; $p=0.003$), Fusobacteria ($r=0.281$; $p=0.049$), and Bacilli ($r=0.314$; $p=0.031$), and negatively correlated with the abundance of Bacteroidetes ($r=-0.313$; $p=0.032$) and Erysipelotrichia ($r=-0.329$; $p=0.024$).

Conclusion. Gut dysbiosis is associated with hyperdynamic circulation, which is associated with a number of complications of cirrhosis.

Introduction

Hemodynamics changes in cirrhosis were described half of a century ago and consist of arterial vasodilation (decreased systemic vascular resistance), hypotension, and increased cardiac output. This is defined as hyperdynamic circulation^[1–3]. The study of experimental models of cirrhosis led to the hypothesis that these changes arise as a response to subclinical systemic inflammation which in turn is a consequence of bacterial translocation, the penetration of bacteria and their components from the intestinal contents into ascitic fluid, mesenteric lymph nodes, and portal and systemic blood flow^[1–7]. Experts suggest that hyperdynamic circulation aggravates portal hypertension, creating a predisposition for the development of various complications of cirrhosis^[3–7]. The main factors contributing to bacterial translocation are increased intestinal barrier permeability, small intestinal bacterial overgrowth (SIBO), and changes in the composition of the gut microbiota (gut dysbiosis)^[4]. The relationship between SIBO,

hyperdynamic circulation, and complications of cirrhosis has been established^[8–9]. However, despite the intensive study of gut dysbiosis, no previous research has described its effect on systemic hemodynamics in cirrhosis^[10–25]. This study aimed to determine the relationship between gut dysbiosis and hemodynamic changes in cirrhosis as well as the relationship between these changes and the complications of this disease.

Materials And Methods

Patients

In this cross-sectional observational study, 100 consecutive patients with cirrhosis were admitted to the Department of Hepatology's Clinic for Internal Diseases, Gastroenterology and Hepatology at Sechenov University (Moscow, Russia) and screened for inclusion. The study procedures were explained to potential participants, and written informed consent was obtained before enrollment. The present study was approved by the Ethics Committee of Sechenov University in accordance with the Declaration of Helsinki.

The inclusion criteria were as follows: diagnosis of cirrhosis verified by histology or clinical, biochemical, and ultrasound findings; and age between 18 and 70 years. The exclusion criteria were as follows: use of lactulose, lactitol, or other prebiotics, probiotics, antibiotics, or metformin in the past 6 weeks; alcohol consumption in the past 6 weeks; or inflammatory bowel disease, cancer, or any other serious disease. Of the original 100 patients screened for inclusion, 47 met the criteria and were enrolled in the study (Fig. 1).

Gut microbiome analysis

The morning after admission, a stool sample was taken into a sterile disposable container and immediately frozen at -80°C^[26].

DNA from the stool was isolated using the MagNa Pure Compact Nucleic Acid Isolation Kit I (Roche, Basel, Switzerland) according to the manufacturer's instructions. Libraries for sequencing were prepared by two rounds of PCR amplification. In the first round, specific primers for the v3-v4 region of the 16S ribosomal RNA gene were used:

16S-F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG and 16S-R GTCTCGTGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGTATCTAATCC.

After amplification, the PCR product was purified using AMPure XP magnetic beads (Beckman Coulter, Brea, CA, USA). Then, a second round of PCR was performed to attach specific adapters and enable multiplexing of the samples. To begin, 5 µL of the first PCR product was added to the reaction after ball cleaning with primers containing Illumina indices (Nextera XT Index v2 Primers; San Diego, CA, USA) and adapter sequences as well as 2× KAPA HiFi HotStart ReadyMix. The amplification products were also purified using AMPure XP beads (Beckman Coulter). The concentrations of the prepared libraries were then measured using a Qubit 2.0 fluorimeter (London, UK) and quantitative PCR. The quality of the libraries was

assessed using the Agilent 2100 Bioanalyzer (Santa Clara, CA, USA). The libraries were mixed in equal proportions and diluted to the required concentration to be run on a MiSeq (Illumina) device. Pair-end readings of 300 + 300 nucleotides were obtained. Reads were trimmed from the 3'-tail with Trimmomatic (Illumina) and then merged into a single amplicon with the MeFiT tool^[27–28]. We did not perform operational taxonomic unit picking; instead, we classified amplicon sequences with the Ribosomal Database Project (RDP) classifier and RDP database^[29].

Systemic hemodynamic assessment

Echocardiography was performed at rest according to the guidelines of the American Society of Echocardiography^[30–33]. The systolic and diastolic blood pressure and heart rate were measured using an automatic oscillometric sphygmomanometer (AND, Japan) simultaneously with the assessment of the stroke volume. Calculations of hemodynamic parameters are presented in Table 1^[30–35].

Table 1
Calculations of hemodynamic parameters

Parameter	Calculation
End-diastolic and end-systolic volume of the left ventricle	Modified Simpson's disk method
Ejection fraction of the left ventricle	((end-diastolic volume)-(end-systolic volume))/(end-diastolic volume)
Stroke volume	(Doppler velocity time integral)×(cross-sectional aorta area) ^[34]
Mean arterial pressure	((systolic blood pressure) + 2×(diastolic blood pressure))/3
Cardiac output	(stroke volume)×(heart rate)
Systemic vascular resistance	(mean arterial pressure)/(cardiac output)
Systolic pulmonary artery pressure	(right atrium pressure estimated from diameter of inferior vena cava and respiratory changes) + 4×(the peak velocity of the tricuspid valve regurgitant jet) ² ^[32–33]
Mean pulmonary artery pressure	0.61×(systolic pulmonary artery pressure) + 2 mmHg ^[35]

The criterion for portopulmonary hypertension was a combination of the presence of signs of portal hypertension and mean pulmonary artery pressure above 25 mm Hg^[36].

No generally accepted criteria for hyperdynamic circulation are available. Therefore, we diagnosed a patient with this disorder if their cardiac output was greater than the mean + 2 standard deviations (5.5 L/min) of healthy individuals examined in the same way during the check-up. The control group (n = 50) did not significantly differ from the patients with cirrhosis in terms of age and gender distribution.

Statistical analysis

Statistical analysis was performed with STATISTICA 10 (StatSoft Inc., Tulsa, OK, USA) and SPSS Statistics (IBM SPSS, Armonk, NY, USA) software. The data are presented as medians[interquartile ranges]. The abundance of taxa of the gut microbiota is presented as a percentage. Differences between continuous variables were assessed with the Mann-Whitney test because many variables were not distributed normally. Fisher's exact test was used to assess the differences between categorical variables. Correlations between variables were computed using Spearman's rank correlation. P-values ≤ 0.05 were considered as statistically significant.

Results

Hyperdynamic circulation was found in 16/47 (34.0%) patients, including 2/19 (10.5%) patients with Child-Pugh class A, 8/18 (44.4% vs. 10.5%; p = 0.024) patients with Child-Pugh class B, and 6/10 (60.0% vs. 10.5%; p = 0.002) patients with Child-Pugh class C.

Patients with hyperdynamic circulation had more severe cirrhosis according to the Child-Pugh scale, lower albumin and prothrombin levels, higher C-reactive protein and total bilirubin levels in the blood, lower systemic vascular resistance, higher left ventricular end-diastolic and stroke volumes, and higher incidences of portopulmonary hypertension, clinically significant ascites (grade 2 and 3 ascites according to the classification of the International Club of Ascites), overt hepatic encephalopathy, hypoalbuminemia, hypoprothrombinemia, systemic inflammation, and severe hyperbilirubinemia than patients without hyperdynamic circulation. No significant difference between the groups of patients was observed for incidences of minimal ascites (grade 1 ascites according to the classification of the International Club of Ascites), mild hyperbilirubinemia, minimal hepatic encephalopathy, and esophageal varices, spleen size, main parameters of complete blood count, heart rate, mean blood pressure, left ventricular ejection fraction, and serum creatinine level. The difference between the groups of patients in mean pulmonary artery pressure, serum sodium and potassium levels almost reached the limit of significance (Table 2).

Table 2
Main indicators of patients with cirrhosis with and without hyperdynamic circulation

	Cirrhosis with hyperdynamic circulation (n = 16)	Cirrhosis without hyperdynamic circulation (n = 31)	p
Age, years	48.5[38.5–53.0]	51.0[37.0–60.0]	0.605
Body mass index, kg/m ²	24.6[22.8–29.3]	23.5[22.3–27.5]	0.307
Male/female	9/7	13/18	0.266
Etiology of cirrhosis: alcohol	6 (37.5%)	7 (22.6%)	> 0.050
autoimmune hepatitis	2 (12.5%)	5(16.2%)	
HBV	1 (6.3%)	5(16.1%)	
HCV	2 (12.5%)	7(22.6%)	
mixed	4 (25.0%)	5(16.1%)	
cryptogenic	1 (6.3%)	2(6.5%)	
Child–Pugh score	9[8–11]	6[6–8]	0.003
End-diastolic volume of the left ventricle, mL	132[120–142]	97[87–107]	< 0.001
Ejection fraction of the left ventricle, %	62.2[60.1–64.4]	60.8[58.7–63.8]	0.296
Stroke volume, mL	80[75–86]	59[55–65]	< 0.001
Heart rate, bpm	76[67–84]	71[65–81]	0.393
Cardiac output, L/min	5.8[5.6–6.7]	4.2[3.8–4.6]	< 0.001
Mean blood pressure, mmHg	83[78–92]	88[78–95]	0.875
Systemic vascular resistance, dyn·s·cm ⁻⁵	1095[1011–1302]	1640[1436–1917]	< 0.001
Mean pulmonary artery pressure, mmHg	20.3[17.3–26.4]	17.3[13.6–20.3]	0.075
Portopulmonary hypertension, n (%)	5 (12.8%)	1 (3.2%)	0.013
Esophageal varices (Grade 1), n (%)	4 (25.5%)	11 (35.5%)	0.349
Esophageal varices (Grade 2–3), n (%)	7 (43.8%)	16 (51.6%)	0.420

	Cirrhosis with hyperdynamic circulation (n = 16)	Cirrhosis without hyperdynamic circulation (n = 31)	p
Minimal hepatic encephalopathy, n (%)	4 (25.0%)	14 (51.2%)	0.151
Overt hepatic encephalopathy, n (%)	9 (56.3%)	8 (23.8%)	0.042
Ascites, n (%)	11 (68.8%)	15 (48.4%)	0.154
Minimal ascites, n (%)	3 (18.8%)	10 (32.3%)	0.266
Clinically significant ascites, n (%)	8 (50.0%)	5 (16.1%)	0.018
Red blood cells, 10 ¹² cell/L	3.7[3.1–4.2]	3.9[3.6–4.5]	0.092
White blood cells, 10 ⁹ cell/L	4.5[3.4–7.3]	3.5[2.8–4.8]	0.127
Platelets, 10 ⁹ cell/L	83[59–107]	81[58–115]	0.955
Serum total protein, g/L	69[63–76]	73[64–78]	0.406
Serum albumin, g/L	31[28–36]	38[32–42]	0.012
Hypoalbuminemia (serum albumin < 35 g/L), n (%)	11 (68.8%)	9 (29.0%)	0.011
Serum total bilirubin, µmol/L	56[40–83]	31[22–55]	0.007
Mild hyperbilirubinemia (total bilirubin = 22–51 µmol/L), n (%)	5 (31.2%)	16 (51.6%)	0.154
Severe hyperbilirubinemia (total bilirubin > 51 µmol/L), n (%)	9 (56.3%)	8 (25.8%)	0.042
Prothrombin index (Quick test), %	52[45–62]	66[57–71]	0.001
Hypoprothrombinemia (prothrombin index < 60%), n (%)	11 (68.8%)	10 (32.3%)	0.019
Creatinine, mg/dL	0.78[0.57–0.91]	0.70[0.62–0.90]	0.875
Serum sodium, mmol/L	140[138–141]	141[140–144]	0.081
Serum potassium, mmol/L	4.2[3.2–4.6]	4.4[4.1–4.7]	0.072
Serum glucose, mmol/L	5.2[4.7–5.6]	5.2[4.6–5.7]	0.946
Alanine aminotransferase, U/L	48[26–127]	36[23–61]	0.225
Aspartate aminotransferase, U/L	77[49–176]	44[29–64]	0.018
Gamma glutamyl transferase, U/L	101[37–166]	59[27–122]	0.795

	Cirrhosis with hyperdynamic circulation (n = 16)	Cirrhosis without hyperdynamic circulation (n = 31)	p
Alkaline phosphatase, U/L	223[176–301]	222[166–310]	0.893
C-reactive protein, mg/L	13.8[8.9–17.1]	2.3[0.5–9.2]	0.002
Systemic inflammation (C-reactive protein > 10 mg/L), n (%)	10 (62.5%)	4 (12.9%)	0.001
Splenic length, cm	15.3[14.0-16.5]	15.7[13.8–19.2]	0.718

None of the included patients had spontaneous bacterial peritonitis, hepatopulmonary or hepatorenal syndrome.

The abundance of Proteobacteria, *Enterobacteriaceae*, Bacilli, *Streptococcaceae*, *Lactobacillaceae*, *Enterococcaceae*, and Fusobacteria were increased and the abundance of Bacteroidetes and Erysipelotrichia were decreased in the gut microbiome of patients with hyperdynamic circulation compared to patients without hyperdynamic circulation (Table 3, Fig. 2).

Table 3
Comparison of the gut microbiome at different taxonomic levels between patients with and without hyperdynamic circulation

Taxa	Cirrhosis with hyperdynamic circulation (n = 16)	Cirrhosis without hyperdynamic circulation (n = 31)	p
Firmicutes	83.7[68.4–91.1]	85.7[69.3–91.0]	0.920
Clostridia	68.5[52.6–83.8]	76.9[62.4–83.2]	0.375
Lachnospiraceae	35.4[22.8–52.7]	36.5[23.6–47.5]	0.902
Ruminococcaceae	17.0[9.7–34.1]	23.7[15.2–36.6]	0.466
Peptostreptococcaceae	0.70[0.15–3.50]	0.22[0.04–0.87]	0.148
Clostridiaceae	0.44[0.07–1.59]	0.10[0.01–0.47]	0.145
Bacilli	6.65[1.53–14.5]	0.91[0.40–4.61]	0.027
Streptococcaceae	2.48[0.42–10.4]	0.44[0.13–3.15]	0.044
Lactobacillaceae	0.34[0.07–1.16]	0.11[0.01–0.38]	0.034
Enterococcaceae	0.04[0.00-0.09]	0.00[0.00-0.04]	0.046
Negativicutes	0.48[0.22–0.78]	0.41[0.08–1.27]	0.849
Veillonellaceae	0.47[0.11–0.76]	0.17[0.02–0.87]	0.296
Erysipelotrichia	0.28[0.09–0.38]	0.65[0.29–1.30]	0.029
Fusobacteria	0.01[0.00-0.09]	0.00[0.00-0.01]	0.026
Bacteroidetes	5.59[1.29–6.37]	6.93[3.26–15.7]	0.049
Bacteroidaceae	1.15[0.17–3.31]	2.22[0.81–4.28]	0.135
Rikenellaceae	0.30[0.01–1.01]	0.30[0.05–0.88]	0.508
Porphyromonadaceae	0.22[0.02–0.42]	0.29[0.08–0.53]	0.204
Prevotellaceae	0.08[0.01–2.71]	0.27[0.01–3.11]	0.400
Actinobacteria	0.72[0.44–1.37]	0.79[0.25–3.06]	0.884
Bifidobacteriaceae	0.44[0.14–1.09]	0.56[0.04–2.17]	0.973
Proteobacteria	2.40[1.16–8.21]	0.65[0.12–2.60]	0.012
Enterobacteriaceae	2.02[0.56–7.63]	0.37[0.02–1.75]	0.008
Verrucomicrobiae	0.01[0.00-1.40]	0.01[0.00-0.85]	0.329
Akkermansiaceae	0.01[0.00-1.39]	0.00[0.00-0.27]	0.222

The systemic vascular resistance value negatively correlated with the abundance of Proteobacteria, *Enterobacteriaceae*, and Fusobacteria. This correlation with the abundance of Bacilli almost reached the limit of significance. Left ventricular end-diastolic volume positively correlated with the abundance of Proteobacteria, *Enterobacteriaceae*, and Fusobacteria. Its negative correlation with the abundance of Erysipelotrichia almost reached the limit of significance. Heart rate was negatively correlated with the abundance of Bacteroidetes. The cardiac output value was positively correlated with the abundance of Proteobacteria, *Enterobacteriaceae*, Fusobacteria, and Bacilli, and negatively correlated with the abundance of Bacteroidetes and Erysipelotrichia. No correlation was observed between the abundance of the main taxa of gut microbiome and mean blood pressure, ejection fraction, and mean pulmonary artery pressure values (Table 4).

Table 4
 Correlation matrix of the main taxa of the gut microbiome and the main hemodynamic parameters in cirrhosis

	EDV	EF	SV	HR	CO	MBP	SVR	MPAP
Clostridia	N.S.	N.S.	N.S.	N.S.	N.S.	N.S.	N.S.	N.S.
Bacilli	N.S.	N.S.	N.S.	N.S.	r = 0.314 p = 0.031	N.S.	r = -0.251 p = 0.088	N.S.
Erysipelotrichia	r = -0.251 p = 0.088	N.S.	r = -0.288 p = 0.049	N.S.	r = -0.329 p = 0.024	N.S.	N.S.	N.S.
Fusobacteria	r = 0.291 p = 0.048	N.S.	N.S.	N.S.	r = 0.281 p = 0.049	N.S.	r = -0.401 p = 0.005	N.S.
Bacteroidetes	N.S.	N.S.	N.S.	r = -0.453 p = 0.001	r = -0.313 p = 0.032	N.S.	N.S.	N.S.
Proteobacteria	r = 0.396 p = 0.006	N.S.	r = 0.373 p = 0.010	N.S.	r = 0.402 p = 0.005	N.S.	r = -0.423 p = 0.003	N.S.
Enterobacteriaceae	r = 0.370 p = 0.011	N.S.	r = 0.348 p = 0.016	N.S.	r = 0.424 p = 0.003	N.S.	r = -0.417 p = 0.004	N.S.

CO – Cardiac output; EDV – End-diastolic volume of the left ventricle; EF – Ejection fraction of the left ventricle; HR – Heart rate; MBP – Mean blood pressure; MPAP – Mean pulmonary artery pressure; N.S. – Not significant; SV – Stroke volume; SVR – Systemic vascular resistance.

Discussion

Hyperdynamic circulation was observed in one-third of patients with cirrhosis, and the frequency of its detection increased with an increase in the Child-Pugh cirrhosis class. The increase in cardiac output was accompanied by a decrease in systemic vascular resistance, with no significant decrease in blood pressure. That is, the state of systemic hemodynamics in most of our patients was compensated by fluid retention and increased heart function, neutralizing the hypotonic effect of systemic vasodilation. The increased cardiac output was due to an increase in venous return to the heart, which led to an increase in

end-diastolic volume. Heart rate and ejection fraction, which are other factors that could increase cardiac output, did not significantly differ between the groups of patients with and without hyperdynamic circulation, indicating their insignificant influence on its development. This is consistent with the underfilling hypothesis, which considers vasodilation as a primary disorder, and fluid retention and increased venous return to the heart with an increase in cardiac output as secondary changes^[2–4].

Notably, an increase in end-diastolic volume is usually characteristic of systolic heart failure, but it is not associated with a decrease in ejection fraction in patients with cirrhosis^[9]. Moreover, the serum level of that biomarker of heart failure as N-terminal brain natriuretic peptide does not depend on ejection fraction, but is associated, on the contrary, with increased heart function in these patients^[37].

Complications of cirrhosis were differently associated with hyperdynamic circulation in our study. Some of them (hypoalbuminemia, hypoprothrombinemia, systemic inflammation, portopulmonary hypertension) were more often in patients with this disorder than in those without it. The presence of others (esophageal varices) was not associated with it. The association of hyperdynamic circulation with complications of cirrhosis from the third group (ascites, hyperbilirubinemia, hepatic encephalopathy) depended on their severity: it was absent in their mild and minimal forms, but their severe forms were associated with it. This may be considered as confirmation of the hypothesis that increased cardiac output aggravates the course of portal hypertension but is not its primary cause. Moreover, our study was cross-sectional and it is not entirely correct to judge causal relationships. The primary question here was whether decreased liver function led to the development of hyperdynamic circulation, whether hyperdynamic circulation worsened liver function, or whether they both exacerbated each other, leading to a vicious circle. Additional studies are required to determine the changes in liver function in patients with the same level of decreased liver function, depending on the presence or absence of hyperdynamic circulation. The incidence of hyperdynamic circulation development should be prospectively investigated and compared between patients with varying degrees of compensation for liver function in the other group of future studies.

Unfortunately, we could not measure the hepatic venous pressure gradient, which is considered to be the main quantitative characteristic of portal hypertension^[38].

Our study is the first to assess the relationship between gut dysbiosis and hemodynamic changes in cirrhosis. Despite disagreements between the results of several previous studies, most indicated that the abundance of bacteria under the Proteobacteria phylum^[10–18,21–23], which contains active endotoxin, and Bacilli class^[13–23], which are capable of bacterial translocation, increase in the gut microbiome with cirrhosis. Thus, an increase in the abundance of these bacteria can be considered a biomarker of gut dysbiosis in cirrhosis. These bacteria are responsible for molecular (endotoxin) and cellular bacterial translocation in cirrhosis^[39].

In this study, the abundance of Bacilli and Proteobacteria increased in patients with hyperdynamic circulation and correlated with the values of the main markers of hyperdynamic circulation, namely systemic vascular resistance and cardiac output. This may support the hypothesis that bacterial

translocation of these bacteria and their components leads to vasodilation and hyperdynamic circulation. A similar relationship is also established for the minor taxon Fusobacteria, which also contain endotoxins. Only one article^[22] reported an increase in the content of these bacteria in the gut microbiome in cirrhosis. This may be due to their low abundance in the gut microbiome, so these bacteria do not attract the attention of researchers.

An interesting finding was the decrease in Bacteroidetes abundance in patients with hyperdynamic circulation, considering these bacteria also have endotoxins. The abundance of these bacteria does not correlate with the degree of vasodilation but is associated with a decrease in heart rate, which can prevent the development of hyperdynamic circulation. The mechanism by which Bacteroidetes affect the heart rate is not clear. It seems that the presence of endotoxin is not an indicator of bacterial pathogenicity and its ability to translocate. It should be remembered that Bacteroidetes, together with bacteria under the Clostridia class, are the main taxa of normal human microbiota, and changes in their abundance in cirrhosis compared with healthy individuals are reported differently in different publications. Bacteroidetes abundance either increases^[11, 24], decreases^[10, 19, 22], does not change^[21], or changes depending on the state of liver function^[16] in cirrhosis. Bacteroidetes showed a protective effect against hyperdynamic circulation in our study.

The abundance of beneficial bacteria under the Clostridia class in the gut microbiome does not significantly differ between patients with and without hyperdynamic circulation and does not correlate with any of the hemodynamic parameters in cirrhosis.

An unexpected finding was the negative correlation between markers of hyperdynamic circulation and the abundance of Erysipelotrichia that are a minor class under the Firmicutes phylum. Among the 4 main classes under this phylum, it is the least studied and might be underestimated by researchers.

Changes in the gut microbiome in hemodynamic circulation mainly signifies a redistribution of the proportion of bacteria containing endotoxins, where Proteobacteria and Fusobacteria that have active endotoxins replace Bacteroidetes that have weak endotoxins^[40] (Fig. 2).

Probiotics, which are living bacteria used for dysbiosis, showed their effects on hemodynamic parameters in cirrhosis in small uncontrolled studies, which require randomized controlled trials to confirm^[41].

Our study is the first to confirm that gut dysbiosis is associated with hemodynamic changes in cirrhosis. We further showed that the presence of these changes is associated with a number of complications of cirrhosis. Thus, hemodynamic changes may be considered a pathogenetic link between gut dysbiosis and these complications of cirrhosis. However, this hypothesis requires verification in further prospective studies, the ideas of which we also proposed. All of these contribute to the strength of our study.

The limitation of our study is its small sample size, although this did not prevent us from obtaining significant results.

In conclusion, we have shown that gut dysbiosis is associated with hyperdynamic circulation, which in turn is associated with a number of complications of cirrhosis.

Declarations

Funding: supported by BIOCODEX MICROBIOTA FOUNDATION (National Research Grant Russia 2019).

Conflicts of interest: No.

Ethics approval and Consent to participate: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

Consent for publication: Not applicable.

Availability of data and material: The data can be provided upon request to the corresponding author.

Code availability: Not applicable.

Author contributions: Research idea - Vladimir Ivashkin. Study design - Vladimir Ivashkin and Roman Maslennikov. Research and data analysis - all authors. Draft writing - Roman Maslennikov. Draft editing - all authors. Roman Maslennikov is the guarantor.

ACKNOWLEDGEMENTS

The authors are grateful to the staff of the Department of Hepatology: Maria Zharkova, Alexei Lapshin, Shauki Ondos, Petr Tkachenko, Igor Tikhonov and others.

References

1. **Di Pascoli M**, Sacerdoti D, Pontisso P, Angeli P, Bolognesi M. Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis. *J Vasc Res*. 2017;54(2):92-99. [PMID: 28402977 DOI: 10.1159/000462974]
2. **Moller S**, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. *Liver Int*. 2018;38(4):570-580. [PMID: 28921803 DOI: 10.1111/liv.13589]
3. **Bolognesi M**, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. *World J Gastroenterol*. 2014;20(10):2555-63. [PMID: 24627591 PMCID: PMC3949264 DOI: 10.3748/wjg.v20.i10.2555]
4. **Ponziani FR**, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. *Expert Rev Gastroenterol Hepatol*. 2018;12(7):641-656 [PMID: 29806487 DOI: 10.1080/17474124.2018.1481747]
5. **Maslennikov R**, Ivashkin V, Efremova I, Poluektova E, Shirokova E. The gut-liver axis in cirrhosis: are hemodynamic changes a missing link? *World J Clin Cases* 2021; in press

6. **Gómez-Hurtado I**, Such J, Sanz Y, Francés R. Gut microbiota-related complications in cirrhosis. *World J Gastroenterol*. 2014;20(42):15624-31. [PMID: 25400446 PMCID: PMC4229527 DOI: 10.3748/wjg.v20.i42.15624]
7. **Simbrunner B**, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. *World J Gastroenterol* 2019;25:5897-5917 [PMID: 31660028 PMCID: PMC6815800 DOI: 10.3748/wjg.v25.i39.5897]
8. **Maslenikov R**, Pavlov C, Ivashkin V. Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis. *Hepatol Int* 2018;12(6):567-576 [PMID: 30284684 DOI: 10.1007/s12072-018-9898-2]
9. **Maslenikov R**, Pavlov C, Ivashkin V. Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis? *Turk J Gastroenterol* 2019;30(11):964-975 [PMID: 31767551 PMCID: PMC6883995 DOI: 10.5152/tjg.2019.18551]
10. **Jin M**, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, Tandon P, Martínez I, Cervera C, Walter J, Abraldes JG. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. *Liver Int*. 2019;39(8):1437-1447. [PMID: 30919578 DOI: 10.1111/liv.14106]
11. **Zeng Y**, Chen S, Fu Y, Wu W, Chen T, Chen J, Yang B, Ou Q. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. *J Viral Hepat*. 2020;27(2):143-155 [PMID: 31600845 DOI: 10.1111/jvh.13216]
12. **Kajihara M**, Koido S, Kanai T, Ito Z, Matsumoto Y, Takakura K, Saruta M, Kato K, Odamaki T, Xiao JZ, Sato N, Ohkusa T. Characterisation of blood microbiota in patients with liver cirrhosis. *Eur J Gastroenterol Hepatol*. 2019;31(12):1577-1583 [PMID: 31441799 PMCID: PMC6844652 DOI: 10.1097/MEG.0000000000001494]
13. **Chen Z**, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, Zhang X, Xu H, Ren J. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. *Front Microbiol*. 2020;11:383. [PMID: 32265857 PMCID: PMC7098974 DOI: 10.3389/fmicb.2020.00383]
14. **Zheng R**, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. *Cancer Med*. 2020;9(12):4232-4250 [PMID: 32281295 PMCID: PMC7300425 DOI: 10.1002/cam4.3045]
15. **Lapidot Y**, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T, Segev S, Koren O, Safran M, Ben-Ari Z. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma. *mSystems*. 2020;5(3):e00153-20. [PMID: 32546668 PMCID: PMC7300357 DOI: 10.1128/mSystems.00153-20]
16. **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol*. 2014;60(5):940-7. [PMID: 24374295 PMCID: PMC3995845 DOI: 10.1016/j.jhep.2013.12.019]

17. **Bajaj JS**, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. *Hepatology*. 2015;62(4):1260-71 [PMID: 25820757 PMCID: PMC4587995 DOI: doi: 10.1002/hep.27819]
18. **Ahluwalia V**, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. *Sci Rep.* 2016;6:26800 [PMID: 27225869 PMCID: PMC4880966 DOI: 10.1038/srep26800]
19. **Liu Y**, Jin Y, Li J, Zhao L, Li Z, Xu J, Zhao F, Feng J, Chen H, Fang C, Shilpakar R, Wei Y. Small Bowel Transit and Altered Gut Microbiota in Patients With Liver Cirrhosis. *Front Physiol.* 2018;9:470 [PMID: 29780327 PMCID: PMC5946013 DOI: 10.3389/fphys.2018.00470]
20. **Inoue T**, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y. Gut Dysbiosis Associated With Hepatitis C Virus Infection. *Clin Infect Dis.* 2018;67(6):869-877 [PMID: 29718124. DOI: 10.1093/cid/ciy205]
21. **Maslenikov R**, Ivashkin V, Efremova I, Alieva A, Kashuh E, Tsvetaeva E, Poluektova E, Shirokova E, Ivashkin K. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. *World J Hepatol* 2021; 13(5): 557-570
22. **Chen Y**, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology* 2011; 54:562–572 [PMID: 21574172 DOI: 10.1002/hep.24423]
23. **Kakiyama G**, Pandak W M , Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. *J Hepatol* 2013;58:949–955 [PMID: 23333527 PMCID: PMC3936319 DOI: 10.1016/j.jhep.2013.01.003]
24. **Bajaj JS**, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. *Clin Gastroenterol Hepatol.* 2019;17(4):756-765 [PMID: 30036646 DOI: 10.1016/j.cgh.2018.07.022]
25. **Zhang L**, Wu YN, Chen T, Ren CH, Li X, Liu GX. Relationship between intestinal microbial dysbiosis and primary liver cancer. *Hepatobiliary Pancreat Dis Int.* 2019;18(2):149-157. [PMID: 30661942 DOI: 10.1016/j.hbpd.2019.01.002]
26. **Fouhy F**, Deane J, Rea MC, et al. The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations. *PLoS ONE* 2015;10:e0119355 [PMID: 25748176 PMCID: PMC4352061 DOI: 10.1371/journal.pone.0119355]
27. **Bolger AM**, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 2014; 30:2114-20 [PMID: 24695404 PMCID: PMC4103590 DOI: 10.1093/bioinformatics/btu170]
28. **Parikh HI**, Koparde VN, Bradley SP, et al. MeFiT: Merging and filtering tool for illumina paired-end reads for 16S rRNA amplicon sequencing. *BMC Bioinformatics* 2016; 17: 491 [PMID: 27905885 PMCID: PMC5134250 DOI: 10.1186/s12859-016-1358-1]

29. **Wang Q**, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy. *Applied and Environmental Microbiology* 2007; **73**:5261–7 [PMID: 17586664 PMCID: PMC1950982 DOI: 10.1128/AEM.00062-07]
30. **Lang RM**, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;**28**(1):1-39.e14. [PMID: 25559473 DOI: 10.1016/j.echo.2014.10.003]
31. **Marwick TH**, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *J Am Soc Echocardiogr*. 2015;**28**(7):727-54. [PMID: 26140936 DOI: 10.1016/j.echo.2015.05.002]
32. **Rudski LG**, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;**23**(7):685-713; quiz 786-8. [PMID: 20620859 DOI: 10.1016/j.echo.2010.05.010]
33. **Bossone E**, D'Andrea A, D'Alto M, Citro R, Argiento P, Ferrara F, Cittadini A, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. *J Am Soc Echocardiogr*. 2013;**26**(1):1-14. [PMID: 23140849 DOI: 10.1016/j.echo.2012.10.009]
34. **Sangkum L**, Liu GL, Yu L, Yan H, Kaye AD, Liu H. Minimally invasive or noninvasive cardiac output measurement: an update. *J Anesth*. 2016;**30**(3):461-80. [PMID: 26961819 DOI: 10.1007/s00540-016-2154-9]
35. **Chemla D**, Castelain V, Humbert M, Hébert JL, Simonneau G, Lecarpentier Y, Hervé P. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. *Chest*. 2004;**126**(4):1313-7. [PMID: 15486398. DOI: 10.1378/chest.126.4.1313]
36. **Fussner LA**, Krowka MJ. Current Approach to the Diagnosis and Management of Portopulmonary Hypertension. *Curr Gastroenterol Rep*. 2016;**18**(6):29. [PMID: 27098816 DOI: 10.1007/s11894-016-0504-2]
37. **Maslenikov R**, Driga A, Ivashkin K, Ivashkin V. NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis. *Gastroenterol Hepatol Bed Bench*. 2011;**11**(4):325-332. [PMID: 30425812; PMCID: PMC6204251]
38. **Ferral H**, Fimmel CJ, Sonnenberg A, Alonso MJ, Aquisto TM. Transjugular Liver Biopsy with Hemodynamic Evaluation: Correlation between Hepatic Venous Pressure Gradient and Histologic Diagnosis of Cirrhosis. *J Clin Imaging Sci*. 2021;**11**:25. [PMID: 33948340; PMCID: PMC8088477 DOI: 10.25259/JCIS_233_2020]
39. **Berg RD**, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. *Infect Immun* 1979;**23**:403-411. [PMID: 154474; doi: 10.1128/IAI.23.2.403-411.1979]

40. Poxton IR, Edmond DM. Biological activity of *Bacteroides* lipopolysaccharide—reappraisal. *Clin Infect Dis.* 1995;20 Suppl 2:S149-53 [PMID: 7548538 DOI: 10.1093/clinids/20.supplement_2.s149]
41. Rincón D, Vaquero J, Hernando A, et al. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. *Liver Int* 2014;34:1504-1512 [PMID: 24661740 DOI: 10.1111/liv.12539]

Figures




Figure 1

CONSORT 2010 Flow Diagram




Figure 2

The composition of the gut microbiome in the patients with and without hyperdynamic circulation